MSB won't need to raise capital until Mar19 if the quarterly cash burn remains constant ... so for the first time in a long time, MSB will have time to focus on things other than capital raisings.
Giving MSB the capacity to work on:
i) discussions with the FDA on getting more RMATs;
ii) if a successful CHF LVAD phase 2b is achieved, work with FDA on accelerated approval pathway with existing RMAT designation + potential to accelerate larger phase 3 program;
iii) partnerships for adult aGVHD, CLBP, RA, CHF; and
iv) compiling the NDA for the phase 3 trial success for pediatric aGVHD.
If capital is required, they won't need to go to the Kentgrove facility as they have approval from NASDAQ to raise capital in the US (which they applied for last year and was accepted).
MSB Price at posting:
$1.47 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)